Cogent Biosciences, Inc.: Cogent Biosciences Announces Posit

- Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable

Related Keywords

Waltham , Illinois , United States , Chicago , American , Andrew Robbins , Christi Waarich , Andrew Wagner , American Society Of Clinical Oncology , Harvard Medical School , Cogent Biosciences Inc , Cogent Research Team , Bezuclastinib Clinical Development , Linkedin , Twitter , Dana Farber Cancer Institute , Nasdaq , Disease Control Rate , Gastrointestinal Stromal Tumors , American Society , Clinical Oncology , Annual Meeting , Senior Physician , Bone Oncology , Associate Professor , Harvard Medical , Chief Executive Officer , Cogent Biosciences , Private Securities Litigation Reform Act , Quarterly Report , Acogent , Iosciences , Nnounces , Positive , Head , Data , Rom , Ngoing , Hase , Beak , Trial , Valuating , Bezuclastinib , Combination , Unitinib , Patients , Gastrointestinal , Tromal , Rumors , Mist ,